Cancer Immunotherapy Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033

Strategic Insights -

The Cancer Immunotherapy Market, which stood at USD 105.7 billion in 2024, is expected to grow to USD 254.6 billion by 2033 at a CAGR of 10.26 percent from 2025 to 2033. This growth is being fueled by the increasing incidence of cancer, research on targeted therapies, and growing awareness about immunotherapy's advantages. The market is driven by growth in various segments, including Cancer Immunomodulators, Monoclonal Antibodies, and Lung Cancer Immunotherapy.

Key Takeaways:

  • The Cancer Immunotherapy Market is projected to reach USD 254.6 billion by 2033, exhibiting a CAGR of 10.26 percent from 2025 to 2033.
  • The market is driven by the increasing incidence of cancer, research on targeted therapies, and growing awareness about immunotherapy's advantages.
  • Cancer immunomodulators are a significant growth-driving segment within immunotherapy, with an increasing global demand for immunomodulators.
  • Monoclonal antibodies are among the most commonly applied immunotherapies in oncology, with drugs like trastuzumab and rituximab showing excellent efficacy.
  • Lung cancer immunotherapy is a major trend, with immune checkpoint inhibitors like pembrolizumab becoming standard therapy for non-small cell lung cancer (NSCLC).
  • Breast cancer immunotherapy is picking up pace, with immune checkpoint inhibitors and monoclonal antibodies demonstrating potential, particularly in triple-negative breast cancer (TNBC).
  • The market is expanding due to government policies promoting early detection and novel treatment solutions.
  • Cancer research centers play a crucial role in bringing basic research to clinical practice, propelling the immunotherapy market growth.

Statistics:

  • The Country Immunotherapy Market is projected to reach USD 274.5 billion in 2033, exhibiting a CAGR of 9.28 percent from 2025 to 2033.
  • The Cancer Immunotherapy Market is expected to grow from USD 105.7 billion in 2024 to USD 254.6 billion by 2033.
  • The global Cancer Immunotherapy Market is expected to reach USD 254.6 billion by 2033 at a CAGR of 10.26 percent.
  • Cancer is one of the leading causes of death globally, with cases predicted to increase dramatically over the next few decades.
  • Approximately 1 in 5 individuals get cancer during their lifetime, around 1 in 9 men and 1 in 12 women succumb to the disease.
  • The number of individuals who survived for 5 years after having cancer was estimated at 53.5 million in 2022.
  • The number of new cancer cases and deaths in 2022 were estimated at 20 million and 9.7 million, respectively.

Sources:

  • The Cancer Immunotherapy Market report, published by ResearchAndMarkets.com, covers the market size and share analysis, growth trends, and forecast report from 2025 to 2033.
  • The report includes information on the global Cancer Immunotherapy Market, including drivers, restraints, products, applications, end-users, and countries.
  • The report also includes insights into the key players in the Cancer Immunotherapy Market, including Amgen Inc., AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc., Novarts AG, Johnson & Johnson, Eli Lily Comapny, and Seattle Genetics Inc.
  • The report is available for purchase on ResearchAndMarkets.com's website.